Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ENSC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal Nasdaq delisting notice due to stockholders' equity deficiency below $2.5 million as of March 31, 2026.
Ensysce Biosciences receives Nasdaq delisting notice for equity deficiency below $2.5M
Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read
Key Changes
-
high
Company failed to meet Nasdaq's $2.5 million stockholders' equity requirement as of March 31, 2026, triggering formal delisting notice on May 21, 2026.
Item 3.01 verify on EDGAR → -
high
Ensysce must submit compliance plan by July 6, 2026 (45 days from notice). If accepted, could receive up to 180 days to regain compliance; if rejected, can appeal to Nasdaq Hearings Panel.
Item 3.01 verify on EDGAR → -
high
Company disclosed no assurance it can regain compliance, even if granted extension. Uncertainty exists around plan acceptance, appeal success, and ability to rebuild equity within deadline.
Item 3.01 verify on EDGAR →
Summary
Ensysce Biosciences disclosed it received a Nasdaq delisting notice on May 21, 2026, for failing to maintain the required $2.5 million in stockholders' equity as of March 31, 2026. The company has until July 6, 2026 to submit a compliance plan. If Nasdaq accepts the plan, Ensysce could receive up to 180 days to restore its equity position; if rejected, the company can appeal to a Nasdaq panel.
Retail investors should understand this is a serious liquidity and capital concern. Delisting would force the stock to trade over-the-counter, reducing liquidity and institutional interest. The company's own disclosure emphasizes uncertainty: there's no guarantee Nasdaq will accept any plan or that Ensysce can raise enough capital within the deadline.
Watch for the company's compliance plan submission by early July and any subsequent capital-raising announcements (equity offerings, debt conversions, or asset sales). If no plan materializes or Nasdaq rejects it, delisting becomes increasingly likely by year-end 2026.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 21, 2026, Ensysce Biosciences Inc. (the “Company”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b) (1) as of March 31, 2026, the Company is subject to delisting unless it submits a plan within 45 days (by July 6, 2026) to regain compliance.
The Company failed to meet Nasdaq's minimum stockholders' equity requirement of $2.5 million as of March 31, 2026. Nasdaq has given the Company until July 6, 2026 (45 days) to submit a compliance plan. If accepted, the Company may receive up to 180 days from May 21, 2026 to regain compliance.
Added in current filing · verify on EDGAR →
The Company intends to actively explore options to regain compliance with Nasdaq listing requirements; however, there can be no assurance that Nasdaq will accept the Company’s plan to regain compliance or that, if the plan is not accepted and the Company appeals, the Panel will accept the plan or that the Company will be able to evidence compliance prior to the expiration of any extension that may be granted to the Company.
The Company disclosed significant uncertainty about its ability to regain compliance. There is no guarantee that Nasdaq will accept its compliance plan, that an appeal would succeed, or that the Company can actually achieve compliance within any granted extension period.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 26, 2026 · How we verify